Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
NGNE
NGNE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NGNE News
Neurogene Reports FY GAAP EPS of -$4.24, Exceeding Expectations
6d ago
seekingalpha
Neurogene Reports 2025 Financial Results and Updates
6d ago
Newsfilter
NEUROGENE INC - FULL ENROLLMENT ACHIEVED AND OVER 50% DOSING IN EMBOLDEN TRIAL; EXPECTED TO FINISH DOSING BY Q2 2026
6d ago
moomoo
NEUROGENE REPORTS FY NET INCOME OF -$90.351 MILLION
6d ago
moomoo
NEUROGENE REPORTS FY OPERATING LOSS OF USD 103.328 MILLION
6d ago
moomoo
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
Mar 11 2026
Newsfilter
Yatsen Holding Reports Q4 Earnings Decline
Mar 02 2026
Benzinga
U.S. Stocks Decline Midway; Dell Shares Surge Over 21%
Feb 27 2026
Benzinga
Autodesk Reports Strong Q4 Earnings, Raises Guidance
Feb 27 2026
Benzinga
FDA Grants Breakthrough Therapy Designation to Neurogene's Gene Therapy
Feb 27 2026
stocktwits
Applied Optoelectronics Reports Strong Q4, Shares Surge
Feb 27 2026
Benzinga
FDA Grants Breakthrough Therapy Designation to NGN-401 for Rett Syndrome
Feb 26 2026
Newsfilter
Neurogene to Participate in Multiple Healthcare Conferences
Feb 05 2026
Newsfilter
Zentalis Pharmaceuticals (ZNTL) Surges 17.65% as Investors Renew Interest
Jan 12 2026
NASDAQ.COM
Neurogene Announces Financial Results for Q3 2025 and Shares Recent Developments
Nov 13 2025
Newsfilter
HC Wainwright & Co. Reaffirms Buy Rating on Neurogene, Increases Price Target to $70
Nov 13 2025
Benzinga
Show More News
